Literature DB >> 25370144

Genetic Polymorphisms in the Dopamine Receptor 2 Predict Acute Pain Severity After Motor Vehicle Collision.

Yawar J Qadri1, Andrey V Bortsov1, Danielle C Orrey1, Robert A Swor2, David A Peak3, Jeffrey S Jones4, Niels K Rathlev5, David C Lee6, Robert M Domeier7, Phyllis L Hendry8, Samuel A Mclean1,8.   

Abstract

OBJECTIVES: Dopaminergic signaling is implicated in nociceptive pathways. These effects are mediated largely through dopamine receptors and modulated in part by dopamine transporters. This study tested the hypothesis that genetic variants in the genes encoding dopamine receptor 2 (DRD2) and the dopamine active transporter (SLC6A3) influence acute pain severity after motor vehicle collision.
MATERIALS AND METHODS: European Americans presenting to the emergency department after motor vehicle collision were recruited. Overall pain intensity in emergency department was assessed using a 0 to 10 numeric rating scale. DNA was extracted from blood samples and genotyping of single-nucleotide polymorphisms (SNPs) in the DRD2 and SLC6A3 gene was performed.
RESULTS: A total of 948 patients completed evaluation. After correction for multiple comparisons, SNP rs6276 at DRD2 showed significant association with pain scores, with individuals with the A/A genotype reporting lower mean pain scores (5.3; 95% confidence interval [CI], 5.1-5.5) than those with A/G (5.9; 95% CI, 5.6-6.1) or G/G (5.7; 95% CI, 5.2-6.2) genotypes (P=0.0027). Secondary analyses revealed an interaction between sex and DRD2 SNPs rs4586205 and rs4648318 on pain scores: females with 2 minor alleles had increased pain intensity, whereas males with 2 minor alleles had less pain than individuals with a major allele (interaction P=0.0019). DISCUSSION: Genetic variants in DRD2 are associated with acute pain after a traumatic stressful event. These results suggest that dopaminergic agents may be useful for the treatment of individuals with acute posttraumatic pain as part of a multimodal opioid-sparing analgesic regimen.

Entities:  

Year:  2015        PMID: 25370144      PMCID: PMC4417662          DOI: 10.1097/AJP.0000000000000167

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  61 in total

1.  Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.

Authors:  John Houston; Sweta Dharia; Jeffrey R Bishop; Vicki L Ellingrod; Bonnie Fijal; Jennie G Jacobson; Vicki P Hoffmann
Journal:  Psychiatry Res       Date:  2010-11-20       Impact factor: 3.222

2.  Influence of the dopamine D2 receptor (DRD2) genotype on neuroadaptive effects of alcohol and the clinical outcome of alcoholism.

Authors:  U Finckh; H Rommelspacher; S Kuhn; P Dufeu; G Otto; A Heinz; M Dettling; M Giraldo-Velasquez; J Pelz; K J Gräf; H Harms; T Sander; L G Schmidt; A Rolfs
Journal:  Pharmacogenetics       Date:  1997-08

3.  Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers.

Authors:  E G Jönsson; M M Nöthen; F Grünhage; L Farde; Y Nakashima; P Propping; G C Sedvall
Journal:  Mol Psychiatry       Date:  1999-05       Impact factor: 15.992

4.  Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli.

Authors:  Luda Diatchenko; Andrea G Nackley; Gary D Slade; Kanokporn Bhalang; Inna Belfer; Mitchell B Max; David Goldman; William Maixner
Journal:  Pain       Date:  2006-07-11       Impact factor: 6.961

5.  Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample.

Authors:  Weihua Huang; Thomas J Payne; Jennie Z Ma; Joke Beuten; Randolph T Dupont; Naohiro Inohara; Ming D Li
Journal:  Neuropsychopharmacology       Date:  2008-03-19       Impact factor: 7.853

6.  Growth hormone response to placebo, apomorphine and growth hormone releasing hormone in abstinent alcoholics and control subjects.

Authors:  G A Wiesbeck; T Mueller; N Wodarz; E Davids; T Kraus; J Thome; H G Weijers; J Boening
Journal:  Drug Alcohol Depend       Date:  1998-09-01       Impact factor: 4.492

7.  The association of the dopamine transporter gene and the dopamine receptor 2 gene with delirium, a meta-analysis.

Authors:  Barbara C van Munster; Sophia E J A de Rooij; Mojgan Yazdanpanah; Pentti J Tienari; Kaisu H Pitkälä; Robert J Osse; Dimitrios Adamis; Orla Smit; Marijke S van der Steen; Miriam van Houten; Terhi Rahkonen; Raimo Sulkava; Jouko V Laurila; Timo E Strandberg; Joke H M Tulen; Louwerens Zwang; Alastair J D MacDonald; Adrian Treloar; Eric J G Sijbrands; Aeilko H Zwinderman; Johanna C Korevaar
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

8.  Associations between polymorphisms in dopamine neurotransmitter pathway genes and pain response in healthy humans.

Authors:  Roi Treister; Dorit Pud; Richard P Ebstein; Efrat Laiba; Edith Gershon; May Haddad; Elon Eisenberg
Journal:  Pain       Date:  2009-09-30       Impact factor: 6.961

9.  Association study between clinical response to rizatriptan and some candidate genes.

Authors:  Carlo Asuni; Allesandra Cherchi; Donatella Congiu; Maria P Piccardi; Maria Del Zompo; Maria E Stochino
Journal:  J Headache Pain       Date:  2007-06-11       Impact factor: 7.277

10.  Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease--a Mendelian Randomisation study.

Authors:  Patrick Linsel-Nitschke; Anika Götz; Jeanette Erdmann; Ingrid Braenne; Peter Braund; Christian Hengstenberg; Klaus Stark; Marcus Fischer; Stefan Schreiber; Nour Eddine El Mokhtari; Arne Schaefer; Jürgen Schrezenmeir; Jürgen Schrezenmeier; Diana Rubin; Anke Hinney; Thomas Reinehr; Christian Roth; Jan Ortlepp; Peter Hanrath; Alistair S Hall; Massimo Mangino; Wolfgang Lieb; Claudia Lamina; Iris M Heid; Angela Doering; Christian Gieger; Annette Peters; Thomas Meitinger; H-Erich Wichmann; Inke R König; Andreas Ziegler; Florian Kronenberg; Nilesh J Samani; Heribert Schunkert
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

View more
  4 in total

1.  Associations Between Adolescent Chronic Pain and Prescription Opioid Misuse in Adulthood.

Authors:  Cornelius B Groenewald; Emily F Law; Emma Fisher; Sarah E Beals-Erickson; Tonya M Palermo
Journal:  J Pain       Date:  2018-08-09       Impact factor: 5.820

2.  Methodology of AA CRASH: a prospective observational study evaluating the incidence and pathogenesis of adverse post-traumatic sequelae in African-Americans experiencing motor vehicle collision.

Authors:  Sarah D Linnstaedt; JunMei Hu; Andrea Y Liu; April C Soward; Kenneth A Bollen; Henry E Wang; Phyllis L Hendry; Erin Zimny; Christopher Lewandowski; Marc-Anthony Velilla; Kathia Damiron; Claire Pearson; Robert Domeier; Sangeeta Kaushik; James Feldman; Mark Rosenberg; Jeffrey Jones; Robert Swor; Niels Rathlev; Samuel A McLean
Journal:  BMJ Open       Date:  2016-09-06       Impact factor: 2.692

3.  Association between DRD2 and ANKK1 polymorphisms with the deficit syndrome in schizophrenia.

Authors:  Anna Michalczyk; Justyna Pełka-Wysiecka; Jolanta Kucharska-Mazur; Michał Wroński; Błażej Misiak; Jerzy Samochowiec
Journal:  Ann Gen Psychiatry       Date:  2020-06-17       Impact factor: 3.455

4.  Study protocol for a randomised, double-blind, placebo-controlled clinical trial of duloxetine for the treatment and prevention of musculoskeletal pain: altering the transition from acute to chronic pain (ATTAC pain).

Authors:  Daniel H Strauss; Divya R Santhanam; Samuel A McLean; Francesca L Beaudoin
Journal:  BMJ Open       Date:  2019-03-05       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.